Targeting Tregs in Juvenile Idiopathic Arthritis and Juvenile Dermatomyositis—Insights From Other Diseases
Regulatory T cells (Tregs) are believed to be dysfunctional in autoimmunity. Juvenile idiopathic arthritis (JIA) and juvenile dermatomyositis (JDM) result from a loss of normal immune regulation in specific tissues such as joints or muscle and skin, respectively. Here, we discuss recent findings in...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2019-01-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2019.00046/full |
| _version_ | 1818036419519578112 |
|---|---|
| author | Romy E. Hoeppli Anne M. Pesenacker |
| author_facet | Romy E. Hoeppli Anne M. Pesenacker |
| author_sort | Romy E. Hoeppli |
| collection | DOAJ |
| description | Regulatory T cells (Tregs) are believed to be dysfunctional in autoimmunity. Juvenile idiopathic arthritis (JIA) and juvenile dermatomyositis (JDM) result from a loss of normal immune regulation in specific tissues such as joints or muscle and skin, respectively. Here, we discuss recent findings in regard to Treg biology in oligo-/polyarticular JIA and JDM, as well as what we can learn about Treg-related disease mechanism, treatment and biomarkers in JIA/JDM from studies of other diseases. We explore the potential use of Treg immunoregulatory markers and gene signatures as biomarkers for disease course and/or treatment success. Further, we discuss how Tregs are affected by several treatment strategies already employed in the therapy of JIA and JDM and by alternative immunotherapies such as anti-cytokine or co-receptor targeting. Finally, we review recent successes in using Tregs as a treatment target with low-dose IL-2 or cellular immunotherapy. Thus, this mini review will highlight our current understanding and identify open questions in regard to Treg biology, and how recent findings may advance biomarkers and new therapies for JIA and JDM. |
| first_indexed | 2024-12-10T07:10:39Z |
| format | Article |
| id | doaj.art-11e41eef45f54865aa1230dbe6f37d58 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-10T07:10:39Z |
| publishDate | 2019-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-11e41eef45f54865aa1230dbe6f37d582022-12-22T01:58:04ZengFrontiers Media S.A.Frontiers in Immunology1664-32242019-01-011010.3389/fimmu.2019.00046433895Targeting Tregs in Juvenile Idiopathic Arthritis and Juvenile Dermatomyositis—Insights From Other DiseasesRomy E. Hoeppli0Anne M. Pesenacker1Department of Surgery, British Columbia Children's Hospital Research Institute, University of British Columbia, Vancouver, BC, CanadaDivision of Infection and Immunity, Institute of Immunity and Transplantation, University College London, London, United KingdomRegulatory T cells (Tregs) are believed to be dysfunctional in autoimmunity. Juvenile idiopathic arthritis (JIA) and juvenile dermatomyositis (JDM) result from a loss of normal immune regulation in specific tissues such as joints or muscle and skin, respectively. Here, we discuss recent findings in regard to Treg biology in oligo-/polyarticular JIA and JDM, as well as what we can learn about Treg-related disease mechanism, treatment and biomarkers in JIA/JDM from studies of other diseases. We explore the potential use of Treg immunoregulatory markers and gene signatures as biomarkers for disease course and/or treatment success. Further, we discuss how Tregs are affected by several treatment strategies already employed in the therapy of JIA and JDM and by alternative immunotherapies such as anti-cytokine or co-receptor targeting. Finally, we review recent successes in using Tregs as a treatment target with low-dose IL-2 or cellular immunotherapy. Thus, this mini review will highlight our current understanding and identify open questions in regard to Treg biology, and how recent findings may advance biomarkers and new therapies for JIA and JDM.https://www.frontiersin.org/article/10.3389/fimmu.2019.00046/fullregulatory T cellsjuvenile idiopathic arthritisjuvenile dermatomyositisbiomarkertherapy |
| spellingShingle | Romy E. Hoeppli Anne M. Pesenacker Targeting Tregs in Juvenile Idiopathic Arthritis and Juvenile Dermatomyositis—Insights From Other Diseases Frontiers in Immunology regulatory T cells juvenile idiopathic arthritis juvenile dermatomyositis biomarker therapy |
| title | Targeting Tregs in Juvenile Idiopathic Arthritis and Juvenile Dermatomyositis—Insights From Other Diseases |
| title_full | Targeting Tregs in Juvenile Idiopathic Arthritis and Juvenile Dermatomyositis—Insights From Other Diseases |
| title_fullStr | Targeting Tregs in Juvenile Idiopathic Arthritis and Juvenile Dermatomyositis—Insights From Other Diseases |
| title_full_unstemmed | Targeting Tregs in Juvenile Idiopathic Arthritis and Juvenile Dermatomyositis—Insights From Other Diseases |
| title_short | Targeting Tregs in Juvenile Idiopathic Arthritis and Juvenile Dermatomyositis—Insights From Other Diseases |
| title_sort | targeting tregs in juvenile idiopathic arthritis and juvenile dermatomyositis insights from other diseases |
| topic | regulatory T cells juvenile idiopathic arthritis juvenile dermatomyositis biomarker therapy |
| url | https://www.frontiersin.org/article/10.3389/fimmu.2019.00046/full |
| work_keys_str_mv | AT romyehoeppli targetingtregsinjuvenileidiopathicarthritisandjuveniledermatomyositisinsightsfromotherdiseases AT annempesenacker targetingtregsinjuvenileidiopathicarthritisandjuveniledermatomyositisinsightsfromotherdiseases |